As the world continues to grapple with the COVID-19 pandemic, researchers and scientists are relentlessly trying to find a cure to end the death march. Sensing urgency, the vaccine trials on humans have recently begun with the UK and various other nations helming the pioneering process.
The ChAdOx1 vaccine trial in the UK, under the supervision of the University of Oxford’s scientists, began the human trial phase by injecting microbiologist Elisa Granato. Earlier this week, the group of scientists after receiving the green signal from WHO initiated their vaccine trials. “I’m a scientist, so I wanted to try to support the scientific process wherever I can,” Granato told the BBC as she was injected in Oxford, where the trial began this week.
“Since I don’t study viruses, I felt a bit useless these days, so I felt like this is a very easy way for me to support the cause,” she said, as she was injected on her 32nd birthday on Thursday.
The microbiologist is receiving plaudits for undertaking the risky and uncertain trial.
This group will now be observed for the next 48hours, and their monthly progress will be under strict observations. The 80:20 ratio of success to failure never daunted these unsung heroes of the battle.
China has given the official green signal to the third phase of the vaccine trials. Officials quoted as being “highly optimistic about the result” confirmed that this”inactivated” vaccine is developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and the Wuhan Institute of Virology (WIV).
WIV has been under the glare of all nations citing it to be the origin of the Covid-19 and thereby increasing the urgency of the institute to develop a successful vaccine. A total of 96 persons in three age groups have received the vaccine in the first phase of the clinical trial as of April 23. The vaccine has shown excellent safety results so far, and vaccine receivers are still under observation, said the Chinese pharmaceutical company Sinopharm.
Germany joins the race to develop a plausible vaccine for SARS CoV-2 with minimum side effects. The regulatory body PEI approved the country’s first human clinal trials on volunteers for the potential vaccine, which has been developed by German biotech firm Biotech and US giant Pfizer. The expected human trial in Germany will initiate within a few weeks.